Ganglioside GD2 Antibody from KERAFAST, INC.

Search, find, compare suppliers for anti-Ganglioside GD2 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityGanglioside GD2
CloneME361 / ME36.1
Host SpeciesMouse
Reactive Specieshuman
IsotypeIgG2a/kappa
Formatunconjugated
Size100ug
Concentrationn/a
ApplicationsFACS (1:50), IHC (1:50), Binding assays (1:50)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionAnti-Ganglioside GD2 [ME361] Antibody. Target: Ganglioside GD2
Immunogenn/a
Other Namesn/a
Gene, Accession #Accession: CAS Number 65988-71-8; bDGalpNAc(1-4)[aNeu5Ac(2-8)aNeu5Ac(2-3)]bDGalp(1-4)bDGlcp(1-1)Cer
Catalog #EWI023
Price$353
Order / More InfoGanglioside GD2 Antibody from KERAFAST, INC.
Product Specific References
  1. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014 Jan 21;588(2):288-97.
  2. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 1985 Nov;45(11 Pt 2):5670-6.
  3. Iliopoulos, D; Ernst, C; Steplewski, Z; Jambrosic, J A; Rodeck, U; Herlyn, M; Clark, W H; Koprowski, H; Herlyn, D. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.J Natl Cancer Inst. 1989 03 15;81(6):440-4
  4. Pichla, S L; Murali, R; Burnett, R M. The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside.J Struct Biol. 1997 06;119(1):6-16
  5. Pichla, S L; Murali, R; Burnett, R M. Preliminary crystallographic data for an Fab to the melanoma-associated GD2 ganglioside, and the purification of a soluble form of this antigen.Acta Crystallogr D Biol Crystallogr. 1995 01 01;51(Pt 1):124-6
  6. Kieber-Emmons, Thomas; Monzavi-Karbassi, Bejatohlah; Pashov, Anastas; Saha, Somdutta; Murali, Ramachandran; Kohler, Heinz. The promise of the anti-idiotype concept.Front Oncol. 2012;2:196
  7. Vazquez, Ana M H; Rodreguez-Zhurbenko, Nely; Lopez, Ana M V. Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.Front Oncol. 2012;2:170
  8. Agostino, Mark; Yuriev, Elizabeth; Ramsland, Paul A. Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping.PLoS One. 2012;7(4):e35457
  9. Ahmed, Mahiuddin; Goldgur, Yehuda; Hu, Jian; Guo, Hong-Fen; Cheung, Nai-Kong V. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors.PLoS One. 2013;8(5):e63359
  10. Cheung, Nai-Kong V; Guo, Hongfen; Hu, Jian; Tassev, Dimiter V; Cheung, Irene Y. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.Oncoimmunology. 2012 07 01;1(4):477-486
  11. Bernhard, H; Karbach, J; Strittmatter, W; Meyer Zum Buschenfelde, K H; Knuth, A. Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3.Int J Cancer. 1993 09 30;55(3):465-70
  12. Ruf, Peter; Schafer, Beatrix; Eissler, Nina; Mocikat, Ralph; Hess, Juergen; Ploscher, Matthias; Wosch, Susanne; Suckstorff, Ivonne; Zehetmeier, Christine; Lindhofer, Horst. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.J Transl Med. 2012 11 07;10:219
  13. Kieber-Emmons, Thomas; Saha, Somdutta; Pashov, Anastas; Monzavi-Karbassi, Behjatolah; Murali, Ramachandran. Carbohydrate-mimetic peptides for pan anti-tumor responses.Front Immunol. 2014;5:308
  14. Wondimu, Assefa; Zhang, Tianqian; Kieber-Emmons, Thomas; Gimotty, Phyllis; Sproesser, Katrin; Somasundaram, Rajasekharan; Ferrone, Soldano; Tsao, Chun-Yen; Herlyn, Dorothee. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.Cancer Immunol Immunother. 2008 07;57(7):1079-89
  15. Dobrenkov, Konstantin; Cheung, Nai-Kong V. GD2-targeted immunotherapy and radioimmunotherapy.Semin Oncol. 2014 10;41(5):589-612
  16. Diaz-Zaragoza, Mariana; Hernandez-Avila, Ricardo; Viedma-Rodriguez, Rubi; Arenas-Aranda, Diego; Ostoa-Saloma, Pedro. Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review).Oncol Rep. 2015 09;34(3):1106-14
  17. Somasundaram, Rajasekharan; Caputo, Laura; Guerry, DuPont; Herlyn, Dorothee. CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma.J Transl Med. 2005 11 10;3:41
  18. Doronin, Igor I; Vishnyakova, Polina A; Kholodenko, Irina V; Ponomarev, Eugene D; Ryazantsev, Dmitry Y; Molotkovskaya, Irina M; Kholodenko, Roman V. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.BMC Cancer. 2014 04 28;14:295
  19. Cheng, Ming; Ahmed, Mahiuddin; Xu, Hong; Cheung, Nai-Kong V. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.Int J Cancer. 2015 01 15;136(2):476-86
  20. Deppisch, Nina; Ruf, Peter; Eiβler, Nina; Lindhofer, Horst; Mocikat, Ralph. Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.Oncotarget. 2017 01 17;8(3):4520-4529
  21. Airoldi, I; Lualdi, S; Bruno, S; Raffaghello, L; Occhino, M; Gambini, C; Pistoia, V; Corrias, M V. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.Br J Cancer. 2003 05 19;88(10):1527-36
KERAFAST, INC.
KERAFAST, INC.
KERAFAST, INC.
An Absolute Biotech Company
2 Shaker Road, Unit B101
Shirley MA 01464
P: +1-617-336-3228
P: +1-800-546-1760
F: +1-866-727-9826

info@kerafast.com
Tech Support: TechnicalSupport@kerafast.com

https://www.kerafast.com

Profile of KERAFAST, INC.

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.